Correspondence 0001213900-23-025034 from Altamira Therapeutics Ltd. (CYTO) (CIK 0001601936) (CYTOF)
Altamira Therapeutics Ltd. (CYTO) (CIK 0001601936)
Date: March 31, 2023 · CIK: 0001601936 · Accession: 0001213900-23-025034
AI Filing Summary & Sentiment
File numbers found in text: 333-269823
Letter
Re: Altamira Therapeutics Ltd. (the “Company”)
March 31, 2023
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporate Finance
100 F Street, N.E.
Washington, D.C. 20549
Withdrawal of Request for Acceleration
Registration Statement on Form F-1 (File No. 333-269823)
Ladies and Gentlemen:
On March 23, 2023, the Company requested acceleration of the effective date of the above-referenced Registration Statement so that it would become effective at 5:00 PM on Tuesday, March 28, 2023 or as soon thereafter as practicable. We hereby withdraw such request.
Very truly yours,
Altamira Therapeutics Ltd.
Show Raw Text
CORRESP
1
filename1.htm
March 31, 2023
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporate Finance
100 F Street, N.E.
Washington, D.C. 20549
Re: Altamira Therapeutics Ltd. (the “Company”)
Withdrawal of Request for Acceleration
Registration Statement on Form F-1 (File No. 333-269823)
Ladies and Gentlemen:
On March 23, 2023, the Company requested acceleration
of the effective date of the above-referenced Registration Statement so that it would become effective at 5:00 PM on Tuesday, March 28,
2023 or as soon thereafter as practicable. We hereby withdraw such request.
Very truly yours,
Altamira Therapeutics Ltd.
By:
/s/ Thomas Meyer
Name:
Thomas Meyer
Title:
Chief Executive Officer